$2.93
+0.08 (+2.81%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BLRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 8 with posted results
Held by 3 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 13.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)NCT03246529results2023-11-07Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis SessionsRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF | Multiple Myeloma | 180 | 2020-12-22actual | 2026-01-15 |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486results2024-08-28Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 CriteriaNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BL-8040, Pembrolizumab, Chemotherapy | Metastatic Pancreatic Adenocarcinoma | 80 | 2022-09-06actual | 2024-08-28 |
| Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy SubjectsNCT05293171results2025-03-21QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kgRandomized · Triple-masked · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: 1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet) | Healthy Subjects | 38 | 2022-06-01actual | 2025-03-21 |
| Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeNCT02462252Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine | Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome | 11 | Nov 2020actual | 2020-12-29 |
| Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)NCT03154827results2024-09-05Relapse Free SurvivalOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Due to lack of enrollment | Drug: BL-8040, Atezolizumab | Acute Myeloid Leukemia | 1 | 2020-04-01actual | 2024-09-05 |
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsNCT01838395results2024-09-19Safety and TolerabilityNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ara-C, BL-8040 | Acute Myeloid Leukemia | 42 | Mar 2016actual | 2024-09-19 |
| A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy VolunteersNCT02073019Number of subjects with Adverse EventsRandomized · Triple-masked | Phase 1 | Completed | Drug: BL-8040, Placebo | Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) | 33 | Jul 2015actual | 2015-07-31 |
| Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.NCT01990885Incidence of adverse eventsRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: BL-7010, Placebo | Celiac Disease | 40 | Oct 2014actual | 2017-08-18 |
| Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis CNCT01833845results2014-08-28EfficacyOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: due to failure to recruit subjects | Drug: Ribavirin, Hydroxychloroquine | Hepatitis C | 4 | Apr 2014actual | 2014-08-28 |
| Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative ColitisNCT01506362results2014-05-01Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1 Point Decrease in Rectal Bleeding Sub-score or Absolute Rectal Bleeding Subscore of ≤ 1Open-label · Treatment | Phase 2 | Completed | Drug: BL-7040 | Ulcerative Colitis | 22 | May 2013actual | 2014-07-15 |
| Phase IIb-III Study of BL-1020 Small Molecule for SchizophreniaNCT01363349results2014-09-18CognitionRandomized · Double-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet the pre-specified primary efficacy endpoint. | Drug: CYP-1020, Risperidone | Schizophrenia, Cognitive Effect on Schizophrenic Patients | 269 | Mar 2013actual | 2014-09-18 |
| A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021NCT01121380Incidence of adverse eventsRandomized · Double-masked | Phase 1 | Terminatedsponsor's stated reason: Sponsor strategy change | Drug: BL-1021, 1021 | Healthy, Volunteers | 32 | Oct 2011actual | 2014-03-13 |
| Safety and Feasibility of the Injectable BL-1040 ImplantNCT00557531Occurrence of all AEs including but not limited to All MIs CV hospitalization Serious ventricular arrhythmias sustained: Symptomatic heart failure Renal failure Stroke DeathNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Device: BL-1040 | Cardiovascular Disease | 30 | Jan 2010actual | 2012-02-03 |
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II StudyNCT00567710to evaluate the safety and tolerability of two dose rangesRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: BL - 1020, BL - 1020, Placebo, Risperidone | Schizophrenia | 360 | Jul 2009actual | 2010-06-29 |
| Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020NCT00722176changes from baseline in vital signs, laboratory and ECG evaluations, physical/neurological examination, Extrapyramidal Symptom Rating Scale (ESRS), and incidence of adverse events (AEs) and adverse drop-outs (ADOs).Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: BL-1020, BL-1020 10-30 mg, risperidone | Schizophrenia | 220 | Jul 2009actual | 2010-06-29 |
| Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective DisorderNCT00480571To determine the safety and tolerability of two dose ranges (20-40 mg/day, 30-50 mg/day) of BL-1020 tri-mesylate (free base) in subjects with chronic schizophrenia or schizo-affective disorderNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: BL-1020, BL 1020 High Dose | Schizophrenia, Schizoaffective Disorder | 90 | Dec 2007actual | 2009-07-21 |
| A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human SubjectsNCT00374881SafetyRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: Morphine, Morphine, Sorbitol+Phenylephrine, Sorbitol+Phenylephrine+Morphine, Sorbitol low concentration+Phenylephrine+Morphine | Acute Pain | 9 | Jun 2007actual | 2008-04-15 |
| A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET TracerNCT00480246Non-randomized · Open-label | Phase 1 | Completed | Drug: BL 1020, Perphenazine | Healthy | — | — | 2009-07-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19